SUZHOU and SHANGHAI, China, April 23, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the company has filed its annual report on Form 20-F for the full year ended December 31, 2020 with the U.S. Securities and Exchange Commission (“SEC”) on April 23, 2021.

Go here to see the original:
Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2020

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh